Syndax Pharmaceuticals Inc
NASDAQ:SNDX

Watchlist Manager
Syndax Pharmaceuticals Inc Logo
Syndax Pharmaceuticals Inc
NASDAQ:SNDX
Watchlist
Price: 13.08 USD 1.79% Market Closed
Market Cap: 1.1B USD
Have any thoughts about
Syndax Pharmaceuticals Inc?
Write Note

Syndax Pharmaceuticals Inc
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Syndax Pharmaceuticals Inc
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Syndax Pharmaceuticals Inc
NASDAQ:SNDX
Cash from Financing Activities
$264.4m
CAGR 3-Years
22%
CAGR 5-Years
50%
CAGR 10-Years
29%
Abbvie Inc
NYSE:ABBV
Cash from Financing Activities
-$2.8B
CAGR 3-Years
45%
CAGR 5-Years
25%
CAGR 10-Years
1%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Financing Activities
-$6.8B
CAGR 3-Years
0%
CAGR 5-Years
4%
CAGR 10-Years
-3%
Amgen Inc
NASDAQ:AMGN
Cash from Financing Activities
-$5.3B
CAGR 3-Years
0%
CAGR 5-Years
21%
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Financing Activities
-$1.2B
CAGR 3-Years
1%
CAGR 5-Years
-55%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Financing Activities
-$1.5B
CAGR 3-Years
-55%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Syndax Pharmaceuticals Inc
Glance View

Market Cap
1.1B USD
Industry
Biotechnology

Syndax Pharmaceuticals Inc. is carving out a distinctive niche in the biotechnology industry with a focus on developing therapies that modulate critical pathways involved in cancer and severe non-cancer indications. Founded in 2005, Syndax has its sights set on innovative epigenetic and immune-oncology treatments, harnessing the power of scientific breakthroughs to target hard-to-treat conditions. The company's primary approach revolves around inhibiting specific enzymes that alter the expression of genes, thereby reprogramming cancer cells to succumb to therapeutic intervention or effectively arming the immune system to target tumors. This strategic focus is not merely theoretical; it is grounded in a robust pipeline of clinical-stage drug candidates, which they steadily advance through focused research and strategic collaborations. Syndax generates revenue by developing these pioneering treatments and moving them through the rigorous stages of clinical trials towards regulatory approval. The ultimate goal is to bring their breakthrough medications to market, where they can provide significant medical benefits and address unmet needs in the oncology space. Their business model also includes collaborations and partnerships with larger pharmaceutical companies, which often entail milestone payments and royalties. By leveraging these strategic alliances, Syndax not only monetizes its innovations but also gains access to complementary expertise, enhancing its capabilities in developing and commercializing its investigational therapies. Through this two-pronged focus on groundbreaking research and strategic partnerships, Syndax has positioned itself as a dynamic player poised to make significant contributions to the field of medicine.

SNDX Intrinsic Value
14.88 USD
Undervaluation 12%
Intrinsic Value
Price

See Also

What is Syndax Pharmaceuticals Inc's Cash from Financing Activities?
Cash from Financing Activities
264.4m USD

Based on the financial report for Sep 30, 2024, Syndax Pharmaceuticals Inc's Cash from Financing Activities amounts to 264.4m USD.

What is Syndax Pharmaceuticals Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
29%

Over the last year, the Cash from Financing Activities growth was 56%. The average annual Cash from Financing Activities growth rates for Syndax Pharmaceuticals Inc have been 22% over the past three years , 50% over the past five years , and 29% over the past ten years .

Back to Top